Vyliq, formerly known as relecabtagene autotempa, represents a novel development in the treatment of relapsed or refractory primary progressive large B-cell lymphoma (LBCL). This unique therapy utilizes a altered CAR-T cell therapy specifically designed to the B-cell target CD22. Clinical studies… Read More